A recent report from Accenture analyzed the “near-term value” of AI applications in health care to determine how the potential impact of the technology stacks up against the upfront costs of implementation. Results from the report estimated that AI applications in health care could save up to $150 billion annually for the U.S. health care economy by 2026.
A new survey from customer experience agency Verndale found consumers most strongly want healthcare apps to provide the ability to manage appointments. Other most desired features among all patients include providing an alert when an appointment is running late, the ability to refill prescriptions and access to medical records.
Carpe, a skincare startup offering over-the-counter relief for excessive hand and foot sweating to the estimated 365 million hyperhidrosis sufferers worldwide, announced today that it has raised $2.3 million in seed funding. The round was co-led by the Carolina Angel Network and Duke Angel Network, affiliated with the University of North Carolina and Duke University's alumni networks respectively. Other investors include LaunchCapital, Rubicon Venture Capital, and Triangle Angel Partners.
Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
Common Sensing , an evidence-based, data-driven injectable-medicine healthcare company, announced the close of a $6.6 million USD Series A financing. The round was led by Waterline Ventures. New World Health, Royal Philips (NYSE: PHG; AEX: PHIA), and Haselmeier joined the round as well. The funds will be used to accelerate Common Sensing's manufacturing and commercial operations for Gocap™, an IP-protected dose monitoring solution enabling patients and providers to better utilize injectable medicine, including insulin, fertility medications, growth hormones, and others.
XBiotech USA, Inc. (NASDAQ:XBIT) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7.
Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc., today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.
In a major boost to Australia’s digital health sector, the Federal Government has announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre and its R&D consortium of more than 60 technology companies, universities, health networks and research institutes.
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies. The deal sees GSK become an investor in Orchard, with a 19.9 percent equity stake along with a seat on the firm’s board. The UK drugs giant also stands to receive royalties and commercial milestone payments related to the acquired portfolio.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.